EpiGenX Pharmaceuticals

2000 (July 02) - EpigenX - David L Gluck is President

Full page : [HN00SK][GDrive]

Hirinng in 2001 - https://www.newspapers.com/image/188303252/?terms=%22EpigenX%22





EpiGenX Pharmaceuticals Inc.


5385 Hollister Avenue

Santa Barbara, CA 93111


(805) 964-4486



Company Information:

EpiGenesis Pharmaceuticals Inc., is located at Santa Barbara, CA and is a privately held biopharmaceutical company developing inhaled respiratory medicines for the treatment of asthma and chronic obstructive pulmonary disease (COPD).

Epigenesis is focused on inhaled delivery to leverage the enhanced safety profile of topical therapy over systemic therapy. The Company’s lead compound, EPI-12323, is a once daily, small molecule, inhaled non-glucocorticoid steroid that targets the inflammatory and airway obstruction cascade in the irritated lung.

The Company is committed to developing a series of inhaled respiratory medicines through Phase II studies using small molecule discovery methods.

Epigenesis is continuing its product development efforts by observing a broader asthma population in a Phase II clinical study using its new proprietary inhaled dry powder formulation.

2003 grant

Development of Inhibitors of the DNA Methylation Process

Mikovits, Judy Anne

Epigenx Pharmaceuticals, Santa Barbara, CA, United States


"There is now considerable evidence that DNA methylation, by silencing tumor suppressor and mis-match repair genes, has a major role in the causation and progression of cancer and is also involved in abnormal DNA methylation events following HIV (Human Immunodeficiency Virus) infection. In"

2001 (May 09) Press Release - "Yahoo - EpiGenX Rounds Out Scientific Advisory Board with Nobel Laureate"

See [HX000R][GDrive]

Posted on: 05/09/2001

Dr. Yuan-Tseh Lee Joins Fellow Scientists on Biotechnology Company Advisory Board

SANTA BARBARA, Calif.--(BW HealthWire)--May 7, 2001--EpiGenX Pharmaceuticals Inc., announced today that Dr. Yuan-Tseh Lee has joined a distinguished advisory board which has been assembled to guide the Company in the development of epigenetic-based diagnostics and therapies for cancer and infectious disease. The Scientific Advisory Board, composed of leading scientists in the biotechnology and academic community, will be instrumental in accelerating the development and commercialization of the company's technologies.

Dr. Yuan-Tseh Lee joins an elite group including Michael T. Bowers, Ph.D., Professor of Chemistry and Thomas C. Bruice, Ph.D., Professor of Chemistry and Biochemistry from University of California, Santa Barbara; Joseph F. Costello, Ph.D., on the faculty of University of California, San Francisco, Department of Neurological Surgery; Melvin Louis DePamphilis, Ph.D., Section Chief for the Eukaryotic DNA Replication and Gene Expression unit of the Molecular Growth Laboratory at the National Institute of Child Health and Human Development; as well as Jeffrey L. Ebersole, Ph.D., Professor of Oral Health Research and Director, Center for Oral Health Research, from University of Kentucky, College of Dentistry and Arthur D. Riggs, Ph.D., Associate Director of the Beckman Research Institute of the City of Hope National Medical Center.

EpiGenX's Scientific Advisory Board now features expertise covering cancer biology, infectious disease, bioorganic chemistry and mass spectrometry technologies. Epigenetic strategies entail developing the advanced understanding of gene regulation, and its manipulation in order to fight disease, particularly cancer and infections.

"We are extremely honored to have Dr. Lee join our advisory board," commented Larry Bymaster, President and Chief Executive Officer, EpiGenX. "He has unparalleled expertise in molecular beam technology and we are pleased that he has agreed to provide counsel to our team of scientists."

"Dr. Lee is universally recognized as a world leader in design and use of customized state-of-the-art instrumentation for chemical analysis," noted Alec Wodke, Director of Epigenomics, EpiGenX. "We look forward to his guidance in defining the technology directions for our High Throughput Epigenetic applications."

EpiGenX Scientific Advisory Board is now composed of:

  • Michael T. Bowers, Ph.D., a Professor of Chemistry at UCSB, and one of the world's leading scientists in the field of mass spectrometry has served for over 10 years as, Editor, International Journal of Mass Spectrometry and Ion Processes and serves as Associate Editor Journal of the American Chemical Society. Dr. Bowers his Ph.D. in 1966 from the University of Illinois. His Awards include: Nobel Laureate Signature Award of the American Chemical Society (1988); American Chemical Society Award for Outstanding Achievement in Mass Spectrometry (1996); Guggenheim Fellowship (1994); and UCSB Faculty Research Lecturer (1994). He is a Fellow of the American Physical Society and of the American Association for the Advancement of Science.

  • Thomas C. Bruice, Ph.D., a Professor of Chemistry and Biochemistry at UCSB, was listed among the world's 50 most cited chemists for the period from 1984 to 1991. He has been elected a Member of the National Academy of Sciences (1974), a Fellow of the American Academy of Arts and Sciences and a Fellow of the AAAS (1989) as well as the Royal Society of Chemistry. His awards include: NIH Career Development (1979); Lifetime Investigator and MERIT Awards; Guggenheim Fellow (1979); UCSB Faculty Research Award (1970); American Chemical Society Arthur C. Cope Scholar Award (1987), Richard C. Tolman Medal (1979), Repligan Medal in Biochemistry (1987), Alfred Bader Medal in Bioorganic and Bioinorganic Chemistry (1988), and the James Flack Norris Award (1996) in physical organic chemistry.

  • Joseph F. Costello, Ph.D., serves on the faculty at University of California, San Francisco, Department of Neurological Surgery, and is a leading expert in the field of methylation, including identifying non-random and tumor-specific methylation patterns in human malignancies. His awards include the James S. McDonnell Foundation 21st Century Scientist Award. Dr Costello is a member of the Brain Tumor Research Center at UCSF and has had his work featured in editorials published in Nature Genetics, Science, The Scientist and Wired Magazine. He serves as an ad hoc reviewer for Nature Genetics, Proceedings of the National Academy of Science, Cancer Research, and Genes Chromosomes & Cancer.

  • Melvin Louis DePamphilis, Ph.D., is the Section Chief for the Eukaryotic DNA Replication and Gene Expression unit of the Molecular Growth Laboratory at the National Institute of Child Health and Human Development, Bethesda, MD. He previously served as a Laboratory Head and Full Member of the Roche Institute of Molecular Biology, an Adjunct Professor in the Department of Biological Sciences at Columbia University, and a Professor in the Department of Biological Chemistry at Harvard Medical School. Dr. DePamphilis is one of the country's leading experts in the initiation of DNA replication in mammalian chromosomes; gene expression at the beginning of mammalian development. He currently serves on the editorial board of the following journals: Molecular Reproduction and Development, Molecular Biology Reports, Gene Therapy & Molecular Biology, Cell Structure and Function and Molecular and Cellular Biology.

  • Jeffrey L. Ebersole, Ph.D., is Professor of Oral Health Research and Director, Center for Oral Health Research, at University of Kentucky, College of Dentistry. Earlier in his career, he was Professor of Periodontics and Microbiology at The University of Texas Health Center and, in the mid-1980's, Associate Clinical Professor of Oral Biology and Pathophysiology at the Harvard School of Dental Medicine. Dr. Ebersole's research area is B cell biology and antibodies in secretory immunity and periodontal immunobiology. He has had NIH funding for over 25 years. His primary research emphasis is in the development, specificity and functional abilities of antibodies in the oral cavity.

  • Yuan-Tseh Lee, Ph.D., a Nobel laureate in chemistry in 1986, is the current President of Academia Sinica, the highest research institute in Taiwan. In 1986, Lee shared the Nobel Prize in Chemistry with Dudley R. Herschbach and John C. Polanyi for helping to apply the technology and theory of physics to chemistry. In his research, Lee extended Herschbach's "crossed molecular beam technique" to analyze larger and more complex molecules. Dr. Lee received his doctorate from the University of California at Berkeley in 1965. His world-leading laboratory now contains seven very sophisticated molecular beam apparati, which were specially designed to pursue problems, associated with reaction dynamics, photochemical processes, and molecular spectroscopy. His awards include: Alfred P. Sloan Fellow (1969 - 1971); Fellow, American Academy of Arts and Science (1975); Fellow, American Physical Society, (1976); John Simon Guggenheim Fellow (1976 - 1977); Member, National Academy of Sciences (1979); Member, Academia Sinica, Taiwan, China (1980); Ernest O. Lawrence Award, U.S. Department of Energy (1981); Peter Debye Award of Physical Chemistry, American Chemical Society (1986) and the National Medal of Science in 1986.

  • Arthur D. Riggs, Ph.D., a noted molecular biologist, serves as the Chair, Division of Biology, and Associate Director of the Beckman Research Institute of the City of Hope National Medical Center, which has been designated a Comprehensive Cancer Center by NCI. Dr. Riggs' was one of the scientific founders of Genentech. He is a pioneer in developing an understanding of how methylation acts as an epigenetic control. Currently he is studying X chromosome inactivation and the biological roles of DNA methylation. Dr. Riggs' scientific achievements span three decades at City of Hope.

EpiGenX has accepted invitations to make presentations at two industry conferences this month. The company will be presenting at the Innovative Drug Development Conference in New York on May 8th and the C21 Biotech Convergence Conference in Monterey Bay, California on May 23rd.

EpiGenX Pharmaceuticals is pioneering the development of epigenetic-based diagnostics and therapies tailored to the needs of individual patients. Epigenetic strategies entail developing the advanced understanding of gene regulation, and its manipulation in order to fight disease, particularly cancer and infections. The company's technology platforms all involve DNA methylation. EpiGenX has three commercialization pathways. Its drug discovery tools, EpiHiTS(TM) Technology include a suite of high-throughput assays for the rapid discovery of new epigenetic-based drugs. The company is developing novel and safe therapeutics to fight cancer and infectious diseases through epigenetic mechanisms. EpiGenX is also developing a suite of high-throughput diagnostic and epigenomics technologies to generate information on the activity and inactivity of genes in relation to various diseases. EpiGenX Pharmaceuticals, Inc., is located in Santa Barbara, CA. For more information, call 805-964-4486 or log on to http://www.epigenx.com

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). In particular, when used in the preceding discussion, the words "plan," "confident that," "believe," "expect," "intend to" and similar conditional expressions are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties, and actual results could differ materially from those expressed in any forward-looking statements. Such risks and uncertainties include, but are not limited to, market conditions, competitive factors, the ability to successfully complete additional financings and other risks.


EpiGenX Pharmaceuticals, Inc. Mark Wilkinson, [phone number], mark@epigenx.com

or Larry O. Bymaster, [phone number], larry@epigenx.com

or Ken Richards, [phone number], ken@epigenx.com











THIS SUBLEASE (this "Sublease"), dated for reference purposes as of October

24, 2001, is made and entered into by and between EPIGENX PHARMACEUTICALS, INC.,

a California corporation ("EP"), and ARMED FORCES COMMUNICATIONS, INC., a


reference to the following facts:


A. EP is the Tenant under that certain Gross Rent Real Property Lease

dated as of July 12, 2000 (the "ORIGINAL MASTER LEASE") between EP and Patterson

Associates, LLC, a California limited liability company ("MASTER LANDLORD").

B. The Original Master Lease was amended by amendments dated December 18,

2000 and January 18, 2001 (the Original Master Lease, as so amended, is referred

to in this Sublease as the "MASTER LEASE").

C. Under the Master Lease, EP leases certain premises located at 5385

Hollister Avenue in Goleta, California, as more particularly described in the

Master Lease (the "PREMISES").

D. Subtenant desires to sublease a portion of the Premises from EP, and EP

desires to sublease a portion of the Premises to Subtenant, on the terms and

conditions set forth herein. All terms not otherwise defined herein shall have

the meanings given such terms in the Master Lease.


NOW, THEREFORE, in light of the foregoing and in consideration of the

mutual covenants set forth in this Sublease, EP and Subtenant, intending to be

legally bound, agree as follows:


1.1. SUBLEASE. Commencing on the date set forth in SECTION 2, EP subleases

the Premises to Subtenant, and Subtenant subleases the Premises from EP. The

parties estimate that the Premises consist of approximately 2,570 square feet.

This statement of square footage is an approximation that EP and Subtenant agree

is reasonable, and the Minimum Monthly Rent (defined below) is not subject to

revision whether the actual square footage of the Premises is more or less.

1.2 TERMS. This Sublease is subject to all of the terms and conditions of

the Master Lease. Except as provided in SECTION 1.3, Subtenant shall assume and

perform all of EP's obligations under the Master Lease with respect to the

Premises. Each of such terms and conditions of the Master Lease incorporated

herein shall be terms and conditions of this Sublease. When the context

requires, each reference in the Master Lease to Landlord shall be deemed to

refer to EP, and each reference therein to Tenant shall be deemed to refer to

Subtenant; PROVIDED, HOWEVER, that (a) EP shall not be obligated to perform any

act of the Master Landlord under the Master Lease that EP does not have the authority or right to perform, and (b) any

provision of the Master Lease requiring the approval of the Master Landlord

shall be deemed to require the approval of EP and the Master Landlord. As

between EP and Subtenant, any inconsistency between the terms of the Master

Lease and the terms of this Sublease shall be governed by the terms of this


1.3 EXCEPTIONS. All of the terms and conditions contained in the Master

Lease are incorporated herein as fully set forth, except for Sections N/A to the

Master Lease.


The term of this Sublease shall commence NOVEMBER 1. 2001 (the

"COMMENCEMENT DATE"). Such term shall end at midnight, Pacific Standard Time, on

AUGUST 31,2003.


3.1 DUE DILIGENCE INVESTIGATION. As of the Commencement Date, Subtenant

acknowledges that Subtenant will have conducted or will have had the opportunity

to conduct a comprehensive investigation ("DUE DILIGENCE INVESTIGATION") of the

Premises and all other matters that in Subtenant's judgment may affect the value

or suitability of the Premises for Subtenant's purposes or that may influence

Subtenant's willingness to enter this Sublease, including, without limitation,

an inspection or examination of (a) the physical condition, size, and

configuration of the Premises, including access, parking, location, or

accessibility of utilities, the condition of the improvements, the existence of

any hazardous materials, soil or topographical conditions, and earthquake

preparedness; (b) the Master Lease; (c) title; (d) taxes; (e) income and expense

data; (f) insurance costs; (g) permissible uses and zoning or development

entitlements; (h) any applicable covenants, conditions, and restrictions; and

(i) compliance with any federal, state, or local law, statute, rule, or

regulation now or hereafter in effect (including without limitation the

Americans With Disabilities Act of 1990, 42 U.S.C. ss.12101).

3.2 NO REPRESENTATIONS AND WARRANTIES. Subtenant acknowledges that EP would

not sublease the Premises except on an "AS IS" basis, and agrees that (a)

Subtenant accepts the Premises "AS IS" and with all faults; (b) neither EP nor

any of its officers, agents, employees, or representatives has made any

representations or warranties of any kind or nature, whether express or implied,

with respect to the Premises or any of the matters relating thereto; (c) EP has

no duty to make any disclosures concerning the condition of the Premises and/or

the fitness of the Premises for Subtenant's intended use, and Subtenant

expressly waives any duty that EP might have to make any such disclosures; (d)

Subtenant is relying solely on Subtenant's own Due Diligence Investigation; (e)

neither EP nor Master Landlord shall be required to perform any work of

construction, alteration, repair, or maintenance of or to the Premises.

4. USE

Subtenant may use the Premises for office use and storage and for no other

purposes whatsoever without the prior written consent of EP and Master Landlord.




5.1 MINIMUM MONTHLY RENT. During each month of the term of this Sublease,

inimum monthly rent (as defined below) shall be payable in advance on or before

the first day of each month, commencing on the Commencement Date (the "RENT

COMMENCEMENT DATE"). The minimum monthly rent shall be TWO THOUSAND FOUR HUNDRED

FORTY ONE AND ONE HALF Dollars ($2,441.50) per month (the "MINIMUM MONTHLY

RENT"). Until modified by SECTION 5.2, Minimum Monthly Rent shall be payable in

equal monthly installments in the amount set forth above.

5.2 ANNUAL ADJUSTMENT TO RENT. Minimum Monthly Rent shall be adjusted at

the times and in the manner set forth in the Master Lease.

5.3 ADDITIONAL RENT. In addition to the Minimum Monthly Rent payable

pursuant to SECTIONS 5.1 and 5.2, Subtenant shall pay to EP all other amounts

required to be paid by EP to Master Landlord or any other third party under the

terms of the Master Lease (the Minimum Monthly Rent and all other amounts

required to be paid by Subtenant are referred to collectively as "RENT").

5.4 PAYMENT. All Rent payable by Subtenant hereunder shall be paid by

Subtenant to EP not later than the close of business on the date first due,

without prior notice or demand, without offset or reduction. All Rent shall be

payable in lawful money of the United States at such place as EP may designate

to Subtenant from time to time in writing. Rent or increased Rent for any

partial month shall be prorated on the basis of a thirty-day month.

5.5 PREPAID RENT. Concurrently with the execution of this Sublease,

Subtenant shall pay to EP the sum of TWO THOUSAND FOUR HUNDRED FORTY ONE AND ONE

HALF Dollars ($2,441.50), representing the first month's Minimum Monthly Rent.

5.6 SECURITY DEPOSIT. The amount of the Security Deposit shall be TWO

THOUSAND FOUR HUNDRED FORTY ONE AND ONE HALF Dollars ($2,441.50), which shall be

paid concurrently with the execution of this Sublease.


Subtenant shall procure and maintain policies of insurance insuring the

Premises and Subtenant's use of the same with the coverages and amounts equal to

or greater (at Subtenant's election) than those that EP is obligated to procure

under the terms of the Master Lease. Such policies shall further comply with all

of the terms of the Master Lease. Not later than thirty days prior to the

expiration of any such policy, Subtenant shall present to EP evidence of the

renewal of such policies, or the purchase of acceptable replacement policies,

for the ensuing period. All such policies shall name both EP and Master Landlord

as additional insureds and shall provide that they will not be subject to

cancellation without thirty days' prior written notice to EP.


Subtenant shall indemnify, defend with counsel acceptable to EP, and hold

EP harmless from any claims, damages, costs, expenses, and/or causes of action

that may arise or be in any way related to Subtenant's use and occupancy of the





8.1 EVENTS OF DEFAULT. The following events shall constitute an event of

default under this Sublease:

8.1.1 RENT. Subtenant's failure to make timely payments in accordance with


8.1.2 BREACH. Subtenant's failure to honor or perform any other covenant,

condition, or obligation imposed upon Subtenant by this Sublease; or

8.1.3 LEASE. Subtenant's failure to honor or perform any covenant, condition,

or obligation imposed upon EP, as Tenant, under the terms of the Master Lease.

8.2 NOTICE AND CURE. EP shall provide Subtenant written notice of any

default under this Sublease. If the default is attributable to Subtenant's

failure to pay any sums hereunder, or owing under the Master Lease, Subtenant

shall be entitled to cure any such default within three days following the due

date thereof. If the default is attributable to any other acts or omissions of

Subtenant, Subtenant shall be entitled to cure any such default within ten days

of receiving written notice of any such default from EP.

8.3 REMEDIES. If Subtenant fails to cure any default within the applicable

cure period specified in SECTION 8.2, EP may terminate this Sublease upon

delivery of written notice to Subtenant. Upon any such occurrence, in addition

to other remedies available to EP under law, EP immediately shall be entitled to

(a) terminate Subtenant's right to possession of the Premises and evict

Subtenant therefrom through legal process, and (b) to exercise, as to Subtenant,

all of the rights and remedies available to Master Landlord under the Master

Lease, as if all such rights and remedies were set forth verbatim herein.


9.1 ATTORNEYS' FEES. If either party engages counsel to enforce that

party's rights hereunder or to resolve any dispute arising out of or related to

this Sublease, whether or not litigation is commenced, the prevailing party

shall be entitled to recover from the nonprevailing party all reasonable costs

and expenses (including, without limitation, reasonable attorneys' fees, court

costs, and expert witness fees) incurred by the prevailing party.

9.2 INTEGRATION. This Sublease contains all of the agreements of the

parties with respect to the matters contained herein. No prior or

contemporaneous agreement or understanding, oral or written, pertaining to any

such matters shall be effective for any purpose.

9.3 VENUE. If any action or other legal proceeding is filed in connection

with this Sublease, venue for the same shall be had in Santa Barbara County,


9.4 COUNTERPARTS. This Sublease may be executed in any number of

counterparts, each of which shall be an original, but all of which shall

constitute one and the same instrument.

(Signatures appear on the following page.)



IN WITNESS WHEREOF, the undersigned have caused this Sublease to be

executed, effective on the date set forth above.



a California corporation

By /s/ Ken Richards


Title: CFO

Date: Oct. 31, 2001

By /s/ Signature unreadable


Title: CEO

Date: Oct. 31, 2001


EpiGenX Pharmaceuticals, Inc.

5385 Hollister Avenue

Santa Barbara, CA 93111



California corporation.


By /s/ Adam T. Sawyer


Title: President

Date: October 30, 2001

By /s/ Carolyn Gambult


Title: Vice President

Date: October 30, 2001


Market Place Media

26 Castilian Drive

Santa Barbara, CA 93117




Exhibit A Master Lease

2003 - VP makes a move to Nastech Pharma


Nastech names Paul Johnson senior VP, R&D

06-10-2003 Print

Nastech Pharmaceuticals of the USA has recruited Paul Johnson as senior vice president, R&D, and chief scientific officer. Prior to this, Mr Johnson held a similar post with EpiGenX Pharmaceuticals.

Note .. this "Nastech" may have turned into a company that has roots too "Moderna"



Nastech Pharmaceutical Company to Cut 50 Jobs

Feb 13, 2008 10:56am


Nastech Pharmaceutical Company to Cut 50 Jobs

BOTHELL, Wash., Feb. 12 -- Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK - News) announced today that its Board of Directors has approved a plan to further reduce operating expenses and align the company's workforce with its strategic, business and clinical development requirements.

"The workforce reduction of approximately 50 employees will enable us to drive our key clinical development and RNAi programs forward in a more efficient manner for the benefit of our shareholders," stated Steven C. Quay, M.D., Ph.D., Chairman and CEO of Nastech. "The savings by this action are estimated to be not less than $11 million during the 2008 fiscal year."

About Nastech

Nastech is a clinical stage biopharmaceutical company focusing on the development and commercialization of innovative therapeutic products based on its proprietary molecular biology-based drug delivery technologies and, through its wholly-owned subsidiary, MDRNA, Inc., based on its proprietary ribonucleic acid interference technology. Nastech and its collaboration partners are developing products for multiple therapeutic areas including osteoporosis, obesity, diabetes, autism, respiratory diseases and inflammatory conditions. Additional information about Nastech is available at http://www.nastech.com.



Marina Biotech, Inc. (Formerly Known as MDRNA, Inc.) Announces Closure of Cambridge Site and Consolidation of R&D Operations in Bothell, WA

Published: Feb 14, 2012

BOTHELL, WA--(Marketwire - February 14, 2012) - Marina Biotech, Inc. (OTCQX: MRNA), a leading nucleic acid-based drug discovery and development company, today announced the closure of its Cambridge site and the consolidation of all research and development efforts at its headquarters in Bothell, WA. In addition, the Company announced dosing of the first patient in Cohort 2 in the Dose Escalation Phase of the START-FAP (Safety and Tolerability of An RNAi Therapeutic in Familial Adenomatous Polyposis) clinical trial with CEQ508.

"After considerable review, we have decided to close our Cambridge site and transfer those research and development efforts to our headquarters in Bothell, WA," said J. Michael French, President & CEO of Marina Biotech. "This move will not affect the START-FAP trial as noted by our announcement today of Cohort 2 dosing. Further, we expect to continue to develop the tkRNAi platform in our labs in Bothell. The closing of the Cambridge site is consistent with our continued efforts to reduce our cash utilization. The individuals affected by this decision were all part of the former Cequent team who then, and certainly over the past several years, were instrumental to the development of CEQ508 and the successful execution of the START-FAP trial. I want to thank them for their efforts and wish them all well in their future endeavors."

2005 - EpigenX.com website (recovered from Archive.org)










Larry O. Bymaster, Chairman, President & CEO. Prior to joining EpiGenX, Larry Bymaster was President and CEO of Techniclone Corporation, a publicly traded pharmaceutical company focused on cancer therapeutics. From 1990 to 1997, Mr. Bymaster served as Chairman, President and Chief Executive Officer of Xytronyx, Inc./Pacific Pharmaceuticals Inc., a publicly traded (AMEX) research-based cancer therapeutic and diagnostic pharmaceutical products company. Prior to joining Xytronyx, Larry served as executive vice president of the Cytotec Inc., a privately held biotechnology company that developed and commercialized products for diagnosing autoimmune diseases. Previous to Cytotech, he held management positions with Baxter International Corporation and American Hospital Corporation. His areas of expertise include pharmaceuticals, biotechnology, corporate mergers and global marketing.

Ken Richards, M.B.A., Chief Financial Officer. Ken Richards has 20 years experience in corporate and investment banking, including serving as Managing Director with CIBC World Markets in Los Angeles and Toronto, and CFO of a public company. During his career, he has completed many large debt, high yield and equity financings, both in North America and internationally. Ken also serves as a Director of the Venture Coast Biotechnology Institute, a non-profit biotechnology industry organization.

Paul H. Johnson, Ph. D., Vice President, Research & Development and Chief Scientific Officer. Dr. Johnson has over 25 years of experience in research and development, contract research and academic science, leading innovative programs in protein and small molecule drug discovery for cancer, cardiovascular and inflammatory diseases. Prior to joining EpiGenX, Dr. Johnson was Principal Scientist, Cancer Research Department, at Berlex Biosciences, the US Research and Development Center for Schering AG, in Richmond, CA. and Head of the Cell and Molecular Biology Department. Prior to Berlex, Dr. Johnson worked for SRI International (Menlo Park, CA) where he was Director of the Cell and Molecular Biology Laboratory. Dr. Johnson received his Ph.D. in Biochemistry from Roswell Park Cancer Institute, State University of New York.

Neda Mashhoon, Ph.D., Director of Drug Discovery. Dr. Mashhoon has over 12 years experience in designing, performing and optimizing enzyme kinetic assays. She has numerous landmark publications describing the kinetic and chemical mechanisms of the bacterial DNA methyltransferase. She has gained additional expertise in protein engineering and structure determination using X-ray crystallography during her postdoctoral career. Dr. Mashhoon served as research faculty at Ohio State University Medical School where she developed high throughput screening protocols and screened a small molecule library in search of Alzheimer’s Disease drug candidates before joining EpiGenX.

Judy A. Mikovits, Ph.D., Director of Cancer Biology. Dr. Mikovits has over 17 years experience studying hematopoietic cell growth, regulation and tumor biology and has spent more than 8 years studying the role of aberrant methylation in retroviral pathogenesis at the National Cancer Institute (NCI) - Frederick Cancer Research and Development Center, Frederick MD. Before joining EpiGenX she held the position of Senior Scientist & Head, Laboratory of Antiviral Drug Mechanisms at the Screening Technologies, Branch of the NCI with the focus of using high throughput screening technologies (HTS) for the development of antiviral agents directed against molecular targets of HIV-1 and other viruses involved in the pathogenesis of AIDS associated malignancies.

Chatper 1 :

She regaled the patrons with stories about her more than twenty years working at the National

Cancer Institute in Maryland. Or, if they were in the mood for romance, she told them about

meeting David at a conference in Ventura in 1999, getting married at the age of forty-two,

commuting for a few months between the NCI on the East Coast and David’s home in Ventura,

and finally deciding that if she wanted a real marriage she needed to be in the same time zone

as her husband.

It was his gentle magnetism that brought her there, to a place where an accomplished scientist

might be found tending bar at an egalitarian yacht club.

To be nearer to David, she got a job as director of cancer research with a biotech start-up in

Santa Barbara called EpiGenX Pharmaceuticals, which was developing drugs to regulate tumor

suppressor genes, leading to more effective outcomes for cancer treatment. The drugs they

were developing decreased DNA methylation (increased DNA methylation caused silencing of

gene expression), which normally becomes disrupted as cancer spread through the body, thus

causing further downstream damage. The intellectual property for the company was licensed

out of the University of California at Santa Barbara (UCSB) and Judy was intimately involved in

the construction of the lab EpiGenX built, as well as securing two SBIR grants from the NIH.

The company had floundered in the wake of the sluggish economic climate after 9/11. In the

spring of 2005, it was in the process of being bought out by a larger company. EpiGenX had

generated a fair amount of its own intellectual property, but with no funding to pay employees,

Mikovits was the only actual lab employee left. She would still go into the lab every day and run

experiments, but the company had also put her in charge of handling due diligence for the

upcoming sale, which took a few hours every day. Mikovits knew that when the sale went

through she would in all likelihood need to look for a new job.

The sale wouldn’t take place for several months, so on one Friday evening in late 2005, Judy

found herself working behind the bar when then vice-commodore of PBYC, Joe Vetrano, walked

in with his new girlfriend, Karen, an accountant. It would prove to be a moment of serendipity,

with Judy’s candor working in her favor. The three of them a human herpes virus HHV-6. Judy

was intrigued as Karen conveyed the substantial level of impairment and suffering of her boss’s

child. Karen’s boss, Kristin Loomis, had started an organization to go after the virus, called the

HHV-6 Foundation. After Karen had talked for several minutes and Judy excitedly asked a few

questions, Joe initiated, off-handedly, “Judy, maybe you could help them.”

“Yes, Joe, why not—I’ll check it out,” she replied with a grin, taking away their finished drinks.

* * *

Ken Richards joined EpiGenX in September of 2000, as chief financial officer, and recalled

recruiting Mikovits from the NCI in May of 2001. 34 Ken was originally from Canada, having

worked for seventeen years for a Canadian corporate investment bank before transferring with

them to Los Angeles in 1997. He was surprised as a savvy money-man to find that the University

of California at Santa Barbara (UCSB) had a phenomenal science and engineering program, but

no systematic way to bring their research discoveries to market. Richards and two other

ambitious partners founded the Santa Barbara chapter of Tech Coast Angels, the largest angel

funding network in the United States.

It was at a meeting for Tech Coast Angels that Ken was introduced to EpiGenX, and through that

company he would meet Mikovits. He later gushed about her: “Judy was a very well-spoken,

knowledgeable, and dedicated scientist who wanted to do everything possible to find effective

treatments for cancer,” said Richards. On the question of why Mikovits seemed to have both

strong supporters and critics, Richards said, “I tell everybody, Judy is very controversial. Many

people do not like her and many people admire her. I am in the later category. She speaks her

mind. When she develops a view, she is dedicated to that view and will defend it fiercely. She’s

combative in a positive sense, and that tends to irritate some people.”

Richards believed that many of Mikovits’s detractors had fallen victim to an unconscious form

of sexism in which an assertive woman was “viewed as a bitch” while a man making a similarly

impassioned defense of his position would be “admired and respected for his firm stance.” 35 It

seemed like the kind of post-feminist statement that perhaps only a man could make and be

fully heard, especially regarding a disease like ME/CFS that was incorectly thought to only affect

women and had been derogatorily referred to as “Yuppie flu” in its early years, with mocking

press implying that women contracting the disease were overly driven.

Even though Mikovits would eventually leave EpiGenX, her tie with Richards would remain solid

and he would remain a steadfast supporter. In 2011, Richards was putting together a private

equity firm to invest in early stage technology and biotechnology companies. “[We] needed

somebody with a strong science background, the first person I thought of was Judy Mikovits.”

When a few higher-ups asked questions about bringing on this controversial figure, Richards

had several cards to play on Judy’s behalf. In addition to a recommendation from the respected

Frank Ruscetti, Nobel Prize winner Luc Montagnier was very supportive of Judy and wrote

highly of her work and her integrity when he penned a recommendation to the Yorkbridge